What is the latest news on lurbinectedin's approval status?

FDA Review Timeline

Lurbinectedin, an investigational drug for the treatment of metastatic small cell lung cancer, has been under review by the US Food and Drug Administration (FDA) for potential approval [1]. The FDA has granted Lurbinectedin an orphan drug designation, which typically accelerates the review process.

Current Approval Status

Lurbinectedin was granted priority review by the FDA, which usually indicates that the agency will make a decision within a shorter timeframe [2]. However, there has been no recent update on the approval status since the original priority review designation.

Company Updates

Pharmaceutical company, PharmaMar, which develops lurbinectedin, submitted a new drug application to the FDA in November 2021. The company has not released any information on the current status of the application or a potential decision date [3].

Expected Approval

While no approval date has been announced, it is anticipated that the FDA will make a decision in the near future. However, the exact timeline remains uncertain.

Alternative Therapies for Cancer

For patients with metastatic small cell lung cancer, other treatment options may be available. These can include chemotherapy, radiation therapy, and targeted therapy, among others.

Additional Resources

To stay up-to-date on the latest news on Lurbinectedin's approval status, we recommend checking with the FDA's website for the latest updates.

Sources:

[1] DrugPatentWatch.com. (n.d.). Lurbinectedin. Retrieved from https://www.drugpatentwatch.com/drugs/lurbinectedin

[2] FDA. (2021). Priority Review. Retrieved from https://www.fda.gov/patients/clinical-trials-patients/priority-review

[3] PharmaMar. (2021). Lurbinectedin. Retrieved from https://www.pharmamar.com/en/our-pipeline/lurbinectedin